Jane Lynch
Pediatric Endocrinology · San Antonio, TXNPI 1750476164
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (59.4%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Novo Nordisk AS accounts for 85.5% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2019 at $32,803 and has fallen 97.2% since, to $903 in 2025. Among pediatric endocrinology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 92 payments — averaging $478.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$38K
- Novo Nordisk$5K
- BETA Bionics, Inc.$224
- Sanofi-aventis U.S. LLC$147
- Tolmar, Inc.$129
- Kyowa Kirin, Inc.$122
- plus $839 from 14 others
Across 690 payments — averaging $683.74 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$255K
- Boehringer Ingelheim$120K
- Boehringer Ingelheim Pharma GmbH & Co.kg$78K
- Dexcom, Inc.$10K
- Boehringer Ingelheim France S.a.s.$7K
- Daiichi Sankyo Inc.$2K
What the payments were for
- Consulting fees$14,79034%
- Speaking & faculty fees$8752%
- Travel & lodging$26,17159%
- Food & beverage$2,2075%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk AS | 5 | $37,675 |
| Novo Nordisk | 33 | $4,906 |
| BETA Bionics, Inc. | 5 | $224 |
| Sanofi-aventis U.S. LLC | 3 | $147 |
| Tolmar, Inc. | 6 | $129 |
| Kyowa Kirin, Inc. | 6 | $122 |
| Abbott | 6 | $120 |
| Ascendis Pharma Endocrinology Inc | 5 | $114 |
| Eton Pharmaceuticals, Inc. | 1 | $104 |
| Dexcom, Inc. | 1 | $89 |
| Azurity Pharmaceuticals, Inc. | 3 | $64 |
| Insulet Corporation | 3 | $59 |
| Soleno Therapeutics, Inc. | 2 | $56 |
| Pfizer | 3 | $54 |
| Lilly USA, LLC | 3 | $53 |
| Arbor Pharmaceuticals, Inc. | 2 | $36 |
| Medtronic | 2 | $31 |
| Neurocrine Biosciences, Inc. | 1 | $22 |
| AbbVie | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Victoza$4,162
- iLet Bionic Pancreas$391
- iLet Insulin Infusion Kit Inset$130
- iLet Insulin Infusion Kit Contact Detach$130
- Sogroya$110
- Alkindi$104
- KHINDIVI$104
- INCRELEX$104
How this compares
$44,043 in reported general payments places this provider in the 90th percentile of 120 pediatric endocrinology providers in Texas.
Other pediatric endocrinology in San Antonio
- Lauren PankratzSan Antonio$16K
- Carisse OrsiSan Antonio$6K
- Ann StraightSan Antonio$5K
- Elia EscanameSan Antonio$2K
- Maria RayasSan Antonio$1K
- Jose Gamez-GodoyEdinburg$207K
- Virginia AraizaHouston$151K
- Daniel DesalvoHouston$133K
- Amy BurtonPlano$130K
- Susan NunezAustin$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.